LUXZYLA Drug Patent Profile
✉ Email this page to a colleague
When do Luxzyla patents expire, and when can generic versions of Luxzyla launch?
Luxzyla is a drug marketed by Ani Pharms and is included in one NDA.
The generic ingredient in LUXZYLA is penicillamine. There are eighteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the penicillamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Luxzyla
A generic version of LUXZYLA was approved as penicillamine by WATSON LABS INC on June 24th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LUXZYLA?
- What are the global sales for LUXZYLA?
- What is Average Wholesale Price for LUXZYLA?
Summary for LUXZYLA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | LUXZYLA at DailyMed |
Pharmacology for LUXZYLA
| Drug Class | Antirheumatic Agent |
US Patents and Regulatory Information for LUXZYLA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms | LUXZYLA | penicillamine | CAPSULE;ORAL | 209921-001 | May 7, 2019 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
